[조사자료] 세계의 망막 질환 치료제 시장 (2023~2030) : 황반 변성증, 당뇨 망막병증

■ 영문 제목 : Retinal Disorder Treatment Market Size, Share & Trends Analysis Report By Type (Macular Degeneration, Diabetic Retinopathy), By Dosage Form, By Distribution Channel, By Product Type, And Segment Forecasts, 2023 - 2030
	■ 상품코드 : GRV23MR030 ■ 조사/발행회사 : Grand View Research ■ 발행일 : 2023년 2월 ■ 페이지수 : 100 ■ 작성언어 : 영어 ■ 보고서 형태 : PDF ■ 납품 방식 : E메일 (납기:3일) ■ 조사대상 지역 : 세계 ■ 산업 분야 : 의료

■ 판매가격 / 옵션 (부가세 10% 별도)

Single User (1인 열람용)	USD5,950 ⇒환산￦8,032,500	견적의뢰/주문/질문
Multi User (5인 열람용)	USD6,950 ⇒환산￦9,382,500	견적의뢰/주문/질문
Global/corporate License (기업 열람용)	USD8,950 ⇒환산￦12,082,500	견적의뢰/구입/질문

※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.

미국 Grand View Research (그랜드뷰리서치)의 본 조사 보고서는 세계의 망막 질환 치료제 시장 규모가 2023년부터 2030년 사이에 CAGR 9.3% 증가하여, 2030년에는 256.9억 달러에 달할 것으로 전망하고 있습니다. 본 조사 자료는 세계의 망막 질환 치료제 시장을 조사 및 분석하여, 조사 방법 및 범위, 개요, 시장 변동/동향/범위, 종류별 (황반 변성증, 당뇨 망막병증, 기타) 분석, 제형별 (젤, 안과용 액제 및 현탁제, 캡슐 및 정제, 안약, 기타) 분석, 유통 채널별 (병원 약국, 온라인 약국, 소매 약국) 분석, 지역별 (북미, 유럽, 아시아 태평양, 중남미, 중동 및 아프리카) 분석, 경쟁 분석 등의 내용을 게재하고 있습니다. 또한 본 리포트는 Graybug Vision, Inc., Shire (Takeda Pharmaceutical Company Limited), Regeneron Pharmaceuticals Inc., Acucela Inc., Allergan Plc. (Abbvie Inc.), Pfizer, Inc., Bayer Ag, Santan Pharmaceuticals Co. Ltd. 등의 기업 정보가 포함되어 있습니다.
・조사 방법 및 범위
・개요
・시장 변동/동향/범위
・세계의 망막 질환 치료제 시장 규모 : 종류별
- 황반 변성증 치료의 시장 규모
- 당뇨 망막병증 치료의 시장 규모
- 기타 망막 질환 치료제의 시장 규모
・세계의 망막 질환 치료제 시장 규모 : 제형별
- 젤형 망막 질환 치료제의 시장 규모
- 안과용 액제 및 현탁제형 망막 질환 치료제의 시장 규모
- 캡슐 및 정제형 망막 질환 치료제의 시장 규모
- 안약형 망막 질환 치료제의 시장 규모
・세계의 망막 질환 치료제 시장 규모 : 유통 채널별
- 병원 약국 채널의 시장 규모
- 온라인 약국 채널의 시장 규모
- 소매 약국채널의 시장 규모
・세계의 망막 질환 치료제 시장 규모 : 지역별
- 북미의 망막 질환 치료제 시장 규모
- 유럽의 망막 질환 치료제 시장 규모
- 아시아 태평양의 망막 질환 치료제 시장 규모
- 중남미의 망막 질환 치료제 시장 규모
- 중동과 아프리카의 망막 질환 치료제 시장 규모
・경쟁 분석

■ 보고서 개요

Retinal Disorder Treatment Market Growth & Trends

The global retinal disorder treatment market size is expected to reach USD 25.69 billion, expanding at a CAGR of 9.3% from 2023 to 2030, according to a new report by Grand View Research, Inc. Growth in the market is fueled by the increasing prevalence of retinal disorders around the world and the unmet need for affordable and efficient treatments. Furthermore, improved funding by regulatory bodies for R&D associated with ocular disorders is expected to further drive market growth.

Retinal diseases are one of the leading causes of visual impairment among the global population. According to WHO, in 2022, a near or distant vision impairment affects at least 2.2 billion people worldwide. Nearly half of these cases, or around 1 billion, involved vision impairments that either could have been avoided or are still unaddressed. Factors such as changing lifestyles, increased life expectancy, and escalating prevalence of systemic diseases like hypertension and diabetes mellitus are the most common causes of retinal disorders. This demonstrates an unmet need among retinal disorder patients for treatment of the condition.

The rising geriatric population is acting as a driver for the market; age-related macular degeneration (AMD) is one of the leading causes of vision loss in people aged over 65 years. AMD is characterized by the degeneration of an area of the retina known as the macula, which is responsible for central vision. The growing elderly population is expected to create a wider patient pool for the treatment of AMD. For instance, according to a WHO report in 2021, by 2030, 1 in every 6 people in the world will be aged 60 years or over. Furthermore, over this period of time, the population aged over 60 years is expected to increase from 1 billion in 2020 to 1.4 billion.

The high cost associated with retinal disorder treatment poses a threat to the growth of the market. However, increasing efforts from key players operating in the market for developing new products for the enhancement of their product pipeline is expected to drive the market. For instance, in January 2022, Genentech’s Vabysmo was approved by the FDA, the first-in-class bispecific antibody for the treatment of wet age-related macular degeneration and diabetic macular edema. The launch of novel products is expected to propel market growth.

Retinal Disorder Treatment Market Report Highlights

• By type, the macular degeneration segment held the largest market share in 2022, which is attributable to its high prevalence, rising awareness about the disease, and promising pipeline products

• Eye drops dosage form segment is projected to grow at the fastest rate over the forecast period due to its high adoption and ease of use

• Hospital pharmacies held a dominant share of the distribution channel segment in 2022 due to the ease of access and availability of patient records

• North America dominated the global market in 2022 and is expected to grow considerably in the future, owing to the rising prevalence of retinal disorders and the increasing consumer awareness about retinal disorders

• A few of the key players include Regeneron Pharmaceuticals Inc., Shire (Takeda Pharmaceutical Company Limited), Graybug Vision, Inc., Bayer AG, Santen Pharmaceutical Co., Ltd., and Genentech, Inc.

■ 보고서 목차

Table of Contents

Chapter 1 Methodology And Scope
1.1 Market Segmentation And Scope
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 List Of Secondary Sources
1.8 List Of Abbreviations
1.9 Objectives
1.9.1 Objective 1
1.9.2 Objective 2
1.9.3 Objective 3
1.9.4 Objective 4
Chapter 2 Retinal Disorder Treatment Market: Executive Summary
2.1 Market Outlook
2.2 Segment Snapshot
2.3 Competitive Landscape Snapshot
Chapter 3 Retinal Disorder Treatment Market Variables, Trends, & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market
3.2 Epidemiology
3.2.1 Retinal Disorders
3.3 Market Dynamics
3.3.1 Market Drivers Analysis
3.3.1.1 Increasing Prevalence Of Target Diseases
3.3.1.2 Strong Pipeline
3.3.1.3 Increasing Geriatric Population
3.3.1.4 Rising Awareness Of Retinal Disorders
3.3.2 Market Restraint Analysis
3.3.2.1 High Cost Of Treatment Drugs
3.4 Penetration & Growth Prospect Mapping
3.5 Retinal Disorder Treatment: Market Analysis Tools
3.5.1 Industry Analysis – Porter’s
3.5.2 Pestle Analysis
3.5.3 Pipeline Analysis
3.5.4 Major Deals And Strategic Alliances
3.5.4.1 New Product Launch
3.5.4.2 Acquisition
3.5.4.3 Expansion
3.5.4.4 Partnerships
3.5.4.5 Marketing & Promotions
Chapter 4 Retinal Disorder Treatment Market: Segment Analysis, By Type, 2018 – 2030 (USD Million)
4.1 Definition And Scope
4.2 Type Market Share Analysis, 2022 & 2030
4.3 Segment Dashboard
4.4 Global Retinal Disorder Treatment Market, By Type, 2018 To 2030
4.5 Market Size & Forecasts And Trend Analyses, 2018 To 2030
4.5.1 Macular Degeneration
4.5.1.1 Macular Degeneration Market, 2018 – 2030 (USD Million)
4.5.1.2 Dry Macular Degeneration
4.5.1.2.1 Dry Macular Degeneration Market, 2018 – 2030 (USD Million)
4.5.1.3 Wet Macular Degeneration
4.5.1.3.1 Wet Macular Degeneration Market, 2018 – 2030 (USD Million)
4.5.2 Diabetic Retinopathy
4.5.2.1 Diabetic Retinopathy Market, 2018 – 2030 (USD Million)
4.5.3 Others
4.5.3.1 Others Market, 2018 – 2030 (USD Million)
Chapter 5 Retinal Disorder Treatment Market: Segment Analysis, By Dosage Form, 2018 – 2030 (USD Million)
5.1 Definition And Scope
5.2 Dosage Form Market Share Analysis, 2022 & 2030
5.3 Segment Dashboard
5.4 Global Retinal Disorder Treatment Market, By Dosage Form, 2018 To 2030
5.5 Market Size & Forecasts And Trend Analyses, 2018 To 2030
5.5.1 Gels
5.5.1.1 Gels Market, 2018 – 2030 (USD Million)
5.5.2 Eye Solutions & Suspensions
5.5.2.1 Eye Solutions Market, 2018 – 2030 (USD Million)
5.5.3 Capsules & Tablets
5.5.3.1 Capsules & Tablets Market, 2018 – 2030 (USD Million)
5.5.4 Eye Drops
5.5.4.1 Eye Drops Market, 2018 – 2030 (USD Million)
5.5.5 Ointments
5.5.5.1 Ointments Market, 2018 – 2030 (USD Million)
Chapter 6 Retinal Disorder Treatment Market: Segment Analysis, By Distribution Channel, 2018 – 2030 (USD Million)
6.1 Definition And Scope
6.2 Distribution Channel Market Share Analysis, 2022 & 2030
6.3 Segment Dashboard
6.4 Global Retinal Disorder Treatment Market, By Distribution Channel, 2018 To 2030
6.5 Market Size & Forecasts And Trend Analyses, 2018 To 2030
6.5.1 Hospital Pharmacy
6.5.1.1 Hospital Pharmacy Market, 2018 – 2030 (USD Million)
6.5.2 Online Pharmacy
6.5.2.1 Online Pharmacy Market, 2018 – 2030 (USD Million)
6.5.3 Retail Pharmacy
6.5.3.1 Retail Pharmacy Market, 2018 – 2030 (USD Million)
Chapter 7 Retinal Disorder Treatment Market: Segment Analysis, By Region, 2018 – 2030 (USD Million)
7.1 Definition & Scope
7.2 Regional Market Share Analysis, 2022 & 2030
7.3 Regional Market Dashboard
7.4 Regional Market Snapshot
7.5 Swot Analysis, By Factor (Political & Legal, Economic And Technological)
7.5.1 North America
7.5.2 Europe
7.5.3 Asia Pacific
7.5.4 Latin America
7.5.5 MEA
7.6 Market Size, & Forecasts, Trend Analysis, 2018 To 2030
7.7 North America
7.7.1 North America Retinal Disorder Treatment Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.7.2 U.S.
7.7.2.1 U.S. Retinal Disorder Treatment Market, 2018 – 2030 (USD Million)
7.7.2.2 Key Country Dynamics
7.7.2.3 Regulatory Framework
7.7.2.4 Competitive Scenario
7.7.2.5 Investments Scenario
7.7.3 Canada
7.7.3.1 Canada Retinal Disorder Treatment Market, 2018 – 2030 (USD Million)
7.7.3.2 Key Country Dynamics
7.7.3.3 Regulatory Framework
7.7.3.4 Competitive Scenario
7.7.3.5 Investments Scenario
7.8 Europe
7.8.1 Europe Retinal Disorder Treatment Market, 2018 – 2030 (USD Million)
7.8.2 Uk
7.8.2.1 Uk Retinal Disorder Treatment Market, 2018 – 2030 (USD Million)
7.8.2.2 Key Country Dynamics
7.8.2.3 Regulatory Framework
7.8.2.4 Competitive Scenario
7.8.2.5 Investments Scenario
7.8.3 Germany
7.8.3.1 Germany Retinal Disorder Treatment Market, 2018 – 2030 (USD Million)
7.8.3.2 Key Country Dynamics
7.8.3.3 Regulatory Framework
7.8.3.4 Competitive Scenario
7.8.3.5 Investments Scenario
7.8.4 Spain
7.8.4.1 Spain Retinal Disorder Treatment Market, 2018 – 2030 (USD Million)
7.8.4.2 Key Country Dynamics
7.8.4.3 Regulatory Framework
7.8.4.4 Competitive Scenario
7.8.4.5 Investments Scenario
7.8.5 France
7.8.5.1 France Retinal Disorder Treatment Market, 2018 – 2030 (USD Million)
7.8.5.2 Key Country Dynamics
7.8.5.3 Regulatory Framework
7.8.5.4 Competitive Scenario
7.8.5.5 Investments Scenario
7.8.6 Italy
7.8.6.1 Italy Retinal Disorder Treatment Market, 2018 – 2030 (USD Million)
7.8.6.2 Key Country Dynamics
7.8.6.3 Regulatory Framework
7.8.6.4 Competitive Scenario
7.8.6.5 Investments Scenario
7.8.7 Norway
7.8.7.1 Norway Retinal Disorder Treatment Market, 2018 – 2030 (USD Million)
7.8.7.3 Regulatory Framework
7.8.7.4 Competitive Scenario
7.8.7.5 Investments Scenario
7.8.8 Denmark
7.8.8.1 Denmark Retinal Disorder Treatment Market, 2018 – 2030 (USD Million)
7.8.8.2 Key Country Dynamics
7.8.8.3 Regulatory Framework
7.8.8.4 Competitive Scenario
7.8.8.5 Investments Scenario
7.8.9 Sweden
7.8.9.1 Sweden Retinal Disorder Treatment Market, 2018 – 2030 (USD Million)
7.8.9.2 Key Country Dynamics
7.8.9.3 Regulatory Framework
7.8.9.4 Competitive Scenario
7.8.9.5 Investments Scenario
7.9 Asia Pacific
7.9.1 Asia-Pacific Retinal Disorder Treatment Market, 2018 – 2030 (USD Million)
7.9.2 Japan
7.9.2.1 Japan Retinal Disorder Treatment Market, 2018 – 2030 (USD Million)
7.9.2.2 Key Country Dynamics
7.9.2.3 Regulatory Framework
7.9.2.4 Competitive Scenario
7.9.2.5 Investments Scenario
7.9.3 China
7.9.3.1 China Retinal Disorder Treatment Market, 2018 – 2030 (USD Million)
7.9.3.2 Key Country Dynamics
7.9.3.3 Regulatory Framework
7.9.3.4 Competitive Scenario
7.9.3.5 Investments Scenario
7.9.4 India
7.9.4.1 India Retinal Disorder Treatment Market, 2018 – 2030 (USD Million)
7.9.4.2 Key Country Dynamics
7.9.4.3 Regulatory Framework
7.9.4.4 Competitive Scenario
7.9.4.5 Investments Scenario
7.9.5 South Korea
7.9.5.1 South Korea Retinal Disorder Treatment Market, 2018 – 2030 (USD Million)
7.9.5.2 Key Country Dynamics
7.9.5.3 Regulatory Framework
7.9.5.4 Competitive Scenario
7.9.5.5 Investments Scenario
7.9.6 Thailand
7.9.6.1 Thailand Retinal Disorder Treatment Market, 2018 – 2030 (USD Million)
7.9.6.2 Key Country Dynamics
7.9.6.3 Regulatory Framework
7.9.6.4 Competitive Scenario
7.9.6.5 Investments Scenario
7.9.7 Australia
7.9.7.1 Australia Retinal Disorder Treatment Market, 2018 – 2030 (USD Million)
7.9.7.2 Key Country Dynamics
7.9.7.3 Regulatory Framework
7.9.7.4 Competitive Scenario
7.9.7.5 Investments Scenario
7.10 Latin America
7.10.1 Latin America Retinal Disorder Treatment Market, 2018 – 2030 (USD Million)
7.10.2 Brazil
7.10.2.1 Brazil Retinal Disorder Treatment Market, 2018 – 2030 (USD Million)
7.10.2.2 Key Country Dynamics
7.10.2.3 Regulatory Framework
7.10.2.4 Competitive Scenario
7.10.2.5 Investments Scenario
7.10.3 Mexico
7.10.3.1 Mexico Retinal Disorder Treatment Market, 2018 – 2030 (USD Million)
7.10.3.2 Key Country Dynamics
7.10.3.3 Regulatory Framework
7.10.3.4 Competitive Scenario
7.10.3.5 Investments Scenario
7.10.4 Argentina
7.10.4.1 Argentina Retinal Disorder Treatment Market, 2018 – 2030 (USD Million)
7.10.4.2 Key Country Dynamics
7.10.4.3 Regulatory Framework
7.10.4.4 Competitive Scenario
7.10.4.5 Investments Scenario
7.11 MEA
7.11.1 MEA Retinal Disorder Treatment Market, 2018 – 2030 (USD Million)
7.11.2 South Africa
7.11.2.1 South Africa Retinal Disorder Treatment Market, 2018 – 2030 (USD Million)
7.11.2.2 Key Country Dynamics
7.11.2.3 Regulatory Framework
7.11.2.4 Competitive Scenario
7.11.2.5 Investments Scenario
7.11.3 Saudi Arabia
7.11.3.1 Saudi Arabia Retinal Disorder Treatment Market, 2018 – 2030 (USD Million)
7.11.3.2 Key Country Dynamics
7.11.3.3 Regulatory Framework
7.11.3.4 Competitive Scenario
7.11.3.5 Investments Scenario
7.11.4 UAE
7.11.4.1 UAE Retinal Disorder Treatment Market, 2018 – 2030 (USD Million)
7.11.4.2 Key Country Dynamics
7.11.4.3 Regulatory Framework
7.11.4.4 Competitive Scenario
7.11.4.5 Investments Scenario
7.11.5 Kuwait
7.11.5.1 Kuwait Retinal Disorder Treatment Market, 2018 – 2030 (USD Million)
7.11.5.2 Key Country Dynamics
7.11.5.3 Regulatory Framework
7.11.5.4 Competitive Scenario
7.11.5.5 Investments Scenario
Chapter 8 Retinal Disorder Treatment Market – Competitive Analysis
8.1 Recent Developments & Impact Analysis, By Key Market Participants
8.1.1 Ansoff Matrix
8.1.2 Heat Map Analysis
8.2 Company Categorization
8.2.1 Innovators
8.2.2 Market Leaders
8.3 Vendor Landscape
8.3.1 List Of Key Distributors And Channel Partners
8.3.2 Key Customers
8.3.3 Key Company Market Share Analysis, 2022
8.4 Public Companies
8.4.1 Company Market Position Analysis
8.4.2 Company Market Share, By Region
8.4.3 Competitive Dashboard Analysis
8.4.3.1 Market Differentiators
8.5 Private Companies
8.5.1 List Of Key Emerging Companies
8.6 Company Profiles
8.6.1 Graybug Vision, Inc.
8.6.1.1 Company Overview
8.6.1.2 Product Benchmarking
8.6.1.3 Strategic Initiatives
8.6.2 Shire (Takeda Pharmaceutical Company Limited)
8.6.2.1 Company Overview
8.6.2.2 Financial Performance
8.6.2.3 Product Benchmarking
8.6.3 Regeneron Pharmaceuticals Inc.
8.6.3.1 Company Overview
8.6.3.2 Financial Performance
8.6.3.3 Product Benchmarking
8.6.3.4 Strategic Initiatives
8.6.4 Acucela Inc.
8.6.4.1 Company Overview
8.6.4.2 Financial Performance
8.6.4.3 Product Benchmarking
8.6.5 Allergan Plc. (Abbvie Inc.)
8.6.5.1 Company Overview
8.6.5.2 Financial Performance
8.6.5.3 Product Benchmarking
8.6.5.4 Strategic Initiatives
8.6.6 Pfizer, Inc.
8.6.6.1 Company Overview
8.6.6.2 Financial Performance
8.6.6.3 Product Benchmarking
8.6.7 Bayer Ag
8.6.7.1 Company Overview
8.6.7.2 Financial Performance
8.6.7.3 Product Benchmarking
8.6.7.4 Strategic Initiatives
8.6.8 Santen Pharmaceuticals Co. Ltd.
8.6.8.1 Company Overview
8.6.8.2 Financial Performance
8.6.8.3 Product Benchmarking
8.6.8.4 Strategic Initiatives
8.6.9 Genentech, Inc. (F. Hoffmann-La Roche Ltd.)
8.6.9.1 Company Overview
8.6.9.2 Financial Performance
8.6.9.3 Product Benchmarking
8.6.9.4 Strategic Initiatives
8.6.10 Kubota Pharmaceutical Holdings Co., Ltd.
8.6.9.1 Company Overview
8.6.9.2 Financial Performance
8.6.9.3 Product Benchmarking
8.6.9.4 Strategic Initiatives

※본 조사보고서 [세계의 망막 질환 치료제 시장 (2023~2030) : 황반 변성증, 당뇨 망막병증] (코드 : GRV23MR030) 판매에 관한 면책사항을 반드시 확인하세요.

※본 조사보고서 [세계의 망막 질환 치료제 시장 (2023~2030) : 황반 변성증, 당뇨 망막병증] 에 대해서 E메일 문의는 여기를 클릭하세요.

※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!

[이하, 관련 보고서 소개]

글로벌 망막 정맥 폐쇄증 치료 시장 (2023-2030) : 소매 약국, 병원 및 진료소
GRV23NOV283 / Grand View Research / 2023년 9월 / 글로벌 망막 정맥 폐쇄증 치료 시장의 성장과 동향 Grand View Research사의 최신 보고서에 따르면, 세계의 망막 정맥 폐쇄증 치료 시장 규모는 2030년까지 4. 18억 달러에 달할 것으로 예상되며, 2023년부터 2030년까지...Chapter 1. 조사 방법 및 범위 Chapter 2. 개요 Chapter 3. 시장 변동, 동향, 범위 Chapter 4. 세계의 망막 정맥 폐쇄증 치료 시장 : 질환 유형별 예측 및 동향 분석 Chapter 5. 세계의 망막 정맥 폐쇄증 치료 시장 : 치료별 예측 및 동향 분석 Chapter 6. 세계의 망막 정맥 폐쇄증...

글로벌 넓은 목근 성형 치료 시장 (2023-2030) : 남성, 여성
GRV23NOV231 / Grand View Research / 2023년 9월 / 글로벌 넓은 목근 성형 치료 시장의 성장과 동향 Grand View Research사의 새로운 보고서에 따르면, 세계의 넓은 목근 성형 치료 시장 규모는 2030년까지 18억 9,000만 달러에 달할 것으로 예상됩니다. 또한 2023년부터...Chapter 1. 조사 방법 및 범위 Chapter 2. 개요 Chapter 3. 시장 변동, 동향, 범위 Chapter 4. 세계의 넓은 목근 성형 치료 시장 : 성별 예측 및 동향 분석 Chapter 5. 세계의 넓은 목근 성형 치료 시장 : 최종 용도별 예측 및 동향 분석 Chapter 6. 세계의 넓은 목근 성형...

글로벌 아스페르길루스 치료 시장 (2023-2030) : 알레르기성, 만성, 침습성
GRV23NOV045 / Grand View Research / 2023년 9월 / 글로벌 아스페르길루스 치료 시장의 성장 및 동향 Grand View Research사의 최신 보고서에 따르면, 세계의 아스페르길루스 치료 시장 규모는 2023년부터 2030년까지 연평균 3. 99%의 성장률을 기록하여 2030년까지 57. 9억 달러에 달할...Chapter 1. 조사 방법 및 범위 Chapter 2. 개요 Chapter 3. 시장 변수/동향/범위 Chapter 4. 세계의 아스페르길루스 치료 시장 : 유형별 세그먼트 분석 Chapter 5. 세계의 아스페르길루스 치료 시장 : 약품 종류별 세그먼트 분석 Chapter 6. 세계의 아스페르길루스 치료 시장 : 투여 경로별 세그먼트 분석 Chapter 7. 세계의 아스페르길루스 치료...

세계의 가습기 시장 2023-2030 : 제품별 (가열식 가습기, 내장형 가습기), 최종 용도별 (병원, 외래 환자 시설), 지역별 (유럽, 북미)
GRV24JAN113 / Grand View Research / 2023년 11월 / 글로벌 가습기 시장의 성장과 동향 Grand View Research, Inc.사의 최신 보고서에 따르면, 세계의 가습기 시장 규모는 2023년부터 2030년까지 연평균 5.0%의 성장률로 확대되어 2030년에는 10억 달러에 달할 것으로 예상됩니다. 건조한 공기에...1. 조사 방법 및 범위 2. 개요 3. 시장 변수/동향/범위 4. 세계의 가습기 시장 규모 : 제품별 비즈니스 분석 5. 세계의 가습기 시장 규모 : 최종 용도별 비즈니스 분석 6. 세계의 가습기 시장 규모 : 지역별 비즈니스 분석 7. 경쟁 현황...

글로벌 위체류 약물전달 시스템 아웃소싱 시장 (2023-2030) : 정제, 액체, 미립구, 캡슐, 기타
GRV23NOV017 / Grand View Research / 2023년 9월 / 글로벌 위체류 약물전달 시스템 아웃소싱 시장의 성장과 동향 Grand View Research사의 최신 보고서에 따르면, 세계의 위체류 약물전달 시스템 아웃소싱 시장 규모는 2030년까지 22. 7억 달러에 달할 것으로 예상되며, 2023년부터 2030년까지...Chapter 1. 조사 방법 및 범위 Chapter 2. 개요 Chapter 3. 시장 변수/동향/범위 Chapter 4. 세계의 위체류 약물전달 시스템 아웃소싱 시장 : 제형별 분석 Chapter 5. 세계의 위체류 약물전달 시스템 아웃소싱 시장 : 지역별 분석 Chapter 6. 경쟁 현황...